Susquehanna International Securities, Ltd. Argenx Se Call Options Transaction History

Susquehanna International Securities, Ltd.

$389 Million
Q3 2024

Call Options

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $1.24 Million - $1.54 Million	-5,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $2.31 Million - $2.92 Million	-10,700 Reduced 68.15%	5,000 $1.31 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $2 Million - $3.65 Million	15,700 New	15,700 $3.54 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

Price T Rowe Associates Inc Baltimore, MD

5.82M
Shares

$3.67 Billion
0.36% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.51M
Shares

$2.21 Billion
2.99% of portfolio
Janus Henderson Group PLC London, X0

2.48M
Shares

$1.56 Billion
0.72% of portfolio
Capital World Investors Los Angeles, CA

1.7M
Shares

$1.07 Billion
0.15% of portfolio
Avoro Capital Advisors LLC New York, NY

1.24M
Shares

$780 Million
10.11% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Securities, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Securities, Ltd. with notifications on news.

Account